The Latest
-
Report reveals murky picture of clinical trial diversity gains
Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.
-
Q&A
Already on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
-
Drug price negotiations: 5 key dates to watch
As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.
-
Q&A // First 90 Days
UBC crowns Bekki Brown as its new CEO with a clear mandate to grow
The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.
-
After ‘limping along,’ Novavax sees a path forward
With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.
-
FDA’s 2022 drug approvals fall short of recent norms
The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.
-
Q&A
A Moderna tie-up ushers in new era for CytomX
The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.
-
Podcast
Woman of the Week: Genetika+’s Talia Cohen Solal
The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.
-
Profile
Pro sports’ COVID protocols led to real-world data impacts for pharma
After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.
-
The M&A hunt is on — here are the prime targets
Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.
-
Opinion
How biotechs can weather the market storm
Execs at JPM sound off on moves companies can make to survive the challenging market conditions.
-
Space — the next frontier in drug development
Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.
-
Biopharma M&A may get the push it needs in 2023, but with a face lift
A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.
-
Q&A // Biotech Spotlight
Galecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
-
Podcast
Woman of the Week: Form Bio’s Claire Aldridge
The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
-
Biotech Spotlight
Chinook Therapeutics nears the finish line in kidney disease
A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.
-
Making Moves
C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans
A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.
-
Q&A // Biotech Spotlight
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
-
The kindred nature of martial arts and drug development
How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.
-
What’s top of mind for industry execs at JPM?
Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.
-
Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023
As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.
-
Profile
A new mission in menopause — extending the lives of women
Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.
-
Podcast
Woman of the Week: Cambrian BioPharma’s Juliette Han
The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.
-
Nonprofits are bridging R&D’s valley of death
How charitable firms such as Advancium are helping to right the market wrongs of drug development.